Table 2 One way ANOVA results at P < 0.05 for Cmax and AUC 0-inf after administration of 25 mg empagliflozin in German and Egyptian subjects.

From: Pharmacokinetic Evaluation of Empagliflozin in Healthy Egyptian Volunteers Using LC-MS/MS and Comparison with Other Ethnic Populations

Cmax (nMol/L)

AUC0-inf (nMol.h/L)

*Groups

Number of subjects

Mean

S.D., (% C.V.)

Mean

S.D., (% C.V.)

Group 113, 38

6

505

130, (25.74)

3830

825, (21.54)

Group 215

18

610

98.82, (16.20)

4770

797, (16.7)

Group 320

9

606

147, (24.26)

4310

1040, (24.13)

Group 420

9

630

106, (16.83)

4990

1080, (21.64)

Egyptian subjects

6

576

86, (14.93)

4103

427, (10.41)

  1. *Studied groups from pharmacokinetic studies conducted in white German subjects using 25 mg EG13, 15, 20, 38 showed no significant difference at P > 0.05, with P = 0.283 for Cmax and P = 0.064 for AUC0-inf.
  2. Abbreviations: AUC = area under the curve; % C.V. = percent coefficient of variation; S.D. = standard deviation.
Back to article page